Lilly teams up with SanegeneBio in a US$1.2 billion RNAi deal to develop tissue-targeted metabolic therapies using ...

Some stocks are similar to the tortoise in Aesop's famous fable, "The Tortoise and the Hare." Others are like the hare. But ...

Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed ...

Company plans to initiate a Phase 1 study in early 2026 with initial human data expected late 2026 Company's first clinical-stage program headlines a diverse and novel pipeline poised to deliver ...

INLIGHT is currently ongoing at multiple trial sites, including in the US following clearance of an Investigational New Drug (IND) application. Wave has expanded Cohort 2, Cohort 3, and Cohort 4 (600 ...

SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, ...

The Boilermakers started 2-0 under Barry Odom, doubling last season's win total. But Purdue hasn't yet produced competitiveness in the Big Ten. The Boilermakers had more yards in penalties than ...

Responsible for global chickpea losses of around USD 330 million annually, the pest not only threatens chickpeas but also ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

A total of 3 analyst ratings have been received for WAVE Life Sciences, with the consensus rating being Buy. The average ...